Compare RCMT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | KPTI |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.7M | 148.0M |
| IPO Year | N/A | 2013 |
| Metric | RCMT | KPTI |
|---|---|---|
| Price | $18.51 | $8.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $30.00 | $22.17 |
| AVG Volume (30 Days) | 47.0K | ★ 604.4K |
| Earning Date | 03-11-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $309,840,000.00 | $146,067,000.00 |
| Revenue This Year | $16.29 | $3.55 |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $10.72 | ★ N/A |
| Revenue Growth | ★ 13.70 | 0.57 |
| 52 Week Low | $13.18 | $3.51 |
| 52 Week High | $28.27 | $10.38 |
| Indicator | RCMT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 27.81 | 72.22 |
| Support Level | $17.26 | $5.90 |
| Resistance Level | $21.41 | $9.94 |
| Average True Range (ATR) | 0.74 | 0.80 |
| MACD | -0.32 | 0.27 |
| Stochastic Oscillator | 3.86 | 78.22 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.